GPR84 and idiopathic pulmonary fibrosis: GLPG1205 is an antagonist and negative allosteric modulator for GPR84 [195] that was discontinued for the development of IBD due to the negative ORIGIN phase 2 trial (NCT02337608) but showed promising preclinical results in models of idiopathic pulmonary fibrosis [191] and also positive topline results from the proof-of-concept PINTA phase 2 study in IPF patients (NCT03725852).